Mustafa Kendirci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mustafa Kendirci has a total of 145 co-authors. Here are the top co-authors by number of shared publications:
- Fatih Kardaş
Department of Pediatric Nutrition and Metabolism, Medical Faculty, Erciyes University, 38030 Kayseri, Turkey
4 shared publications - Selim Kurtoglu
Department of Pediatric Endocrinology, Faculty of Medicine, Erciyes University, Kayseri, Turkey
4 shared publications - Leyla Akın
Division of Pediatric Endocrinology , Ondokuz Mayıs University Faculty of Medicine , Samsun , Türkiye
3 shared publications - Nihal Hatipoğlu
Department of Pediatric Endocrinology, Faculty of Medicine, Erciyes University, Kayseri, Turkey
3 shared publications - Ümmü Alakuş Sarı
Erciyes University, Faculty of Medicine, Department of Pediatrics, Division of Pediatric Metabolism, Kayseri, Türkiye
3 shared publications - Banu Kadıoğlu Yılmaz
Department of Pediatric Nutrition and Metabolism, Faculty of Medicine, Selçuk University, Konya 42250, Türkiye
2 shared publications
Latest Publications
- Open Access
- 10 March 2026
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 185 (3)
The role of the FT3/FT4 ratio in predicting remission and relapse in pediatric Graves’ disease
Long-term antithyroid drug (ATD) therapy is often required in pediatric Graves’ disease, yet adherence can be challenging. Therefore, identifying reliable predictors of remission and relapse is crucial for optimizing disease management. This study aimed to evaluate the role of the baseline FT3/FT4 ratio in predicting remission and relapse, alongside other potential markers, including TRAb levels, thyroid volume, and body mass index (BMI). This retrospective, single-center study included pediatric patients diagnosed with Graves’ disease and treated with ATDs. Age, sex, BMI, thyroid volume, TRAb, FT3, and FT4 levels were recorded at diagnosis, and the FT3/FT4 ratio was calculated. Remission was defined as maintaining euthyroidism for at least 12 months after discontinuation of ATD therapy, whereas relapse was defined as the recurrence of hyperthyroidism following remission. A total of 55 patients were evaluated. The remission rate was 43.6%, and among those who achieved remission, the relapse rate was 8.3%. No significant association was found between remission and age, sex, BMI, ATD duration, or the FT3/FT4 ratio. However, remission was significantly more likely in patients with TRAb levels < 10 IU/L ( p < 0.05). Additionally, an inverse relationship was observed between thyroid volume and the likelihood of remission. Although the baseline FT3/FT4 ratio did not predict remission, it was significantly higher in patients who experienced relapse. An FT3/FT4 ratio > 0.54 pmol/pmol predicted relapse with 75% sensitivity and 98% specificity (AUC = 0.842; p = 0.048). Conclusion : The baseline FT3/FT4 ratio demonstrated limited value in predicting remission but proved to be a strong indicator of relapse risk in pediatric Graves’ disease. Additionally, lower TRAb levels (< 10 IU/L) and smaller thyroid volumes were associated with higher remission rates. Together, these findings suggest that incorporating the FT3/FT4 ratio, TRAb levels, and thyroid volume into routine assessment may enhance risk stratification and support more personalized treatment approaches for pediatric Graves’ disease. What is Known: • Pediatric Graves’ disease often requires long-term antithyroid drug therapy, and remission rates are variable; TRAb levels and thyroid volume are recognized predictors of remission. What is New: • The baseline FT3/FT4 ratio has limited value in predicting remission but may serve as a strong predictor of relapse, with a ratio 0.54 pmol/pmol showing high specifi city for relapse in pediatric Graves’ disease.
- 10 March 2026
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 185 (3)
Open AccessThe role of the FT3/FT4 ratio in predicting remission and relapse in pediatric Graves’ disease
Long-term antithyroid drug (ATD) therapy is often required in pediatric Graves’ disease, yet adherence can be challenging. Therefore, identifying reliable predictors of remission and relapse is crucial for optimizing disease management. This study aimed to evaluate the role of the baseline FT3/FT4 ratio in predicting remission and relapse, alongside other potential markers, including TRAb levels, thyroid volume, and body mass index (BMI). This retrospective, single-center study included pediatric patients diagnosed with Graves’ disease and treated with ATDs. Age, sex, BMI, thyroid volume, TRAb, FT3, and FT4 levels were recorded at diagnosis, and the FT3/FT4 ratio was calculated. Remission was defined as maintaining euthyroidism for at least 12 months after discontinuation of ATD therapy, whereas relapse was defined as the recurrence of hyperthyroidism following remission. A total of 55 patients were evaluated. The remission rate was 43.6%, and among those who achieved remission, the relapse rate was 8.3%. No significant association was found between remission and age, sex, BMI, ATD duration, or the FT3/FT4 ratio. However, remission was significantly more likely in patients with TRAb levels < 10 IU/L ( p < 0.05). Additionally, an inverse relationship was observed between thyroid volume and the likelihood of remission. Although the baseline FT3/FT4 ratio did not predict remission, it was significantly higher in patients who experienced relapse. An FT3/FT4 ratio > 0.54 pmol/pmol predicted relapse with 75% sensitivity and 98% specificity (AUC = 0.842; p = 0.048). Conclusion : The baseline FT3/FT4 ratio demonstrated limited value in predicting remission but proved to be a strong indicator of relapse risk in pediatric Graves’ disease. Additionally, lower TRAb levels (< 10 IU/L) and smaller thyroid volumes were associated with higher remission rates. Together, these findings suggest that incorporating the FT3/FT4 ratio, TRAb levels, and thyroid volume into routine assessment may enhance risk stratification and support more personalized treatment approaches for pediatric Graves’ disease. What is Known: • Pediatric Graves’ disease often requires long-term antithyroid drug therapy, and remission rates are variable; TRAb levels and thyroid volume are recognized predictors of remission. What is New: • The baseline FT3/FT4 ratio has limited value in predicting remission but may serve as a strong predictor of relapse, with a ratio 0.54 pmol/pmol showing high specifi city for relapse in pediatric Graves’ disease.
- 29 April 2025
- Published by Academician Publishing
- p. 447-466
Lizozomal Depo Hastalıkları ve Görüntüleme Bulguları
- 29 April 2025
- Published by Academician Publishing
- p. 447-466
Lizozomal Depo Hastalıkları ve Görüntüleme Bulguları
- Open Access
- 29 April 2025
- Published by Academician Publishing
Canpolat&Karaman&Kardaş - Temel Pediatrik Nöroradyoloji Nörometabolik ve Heredodejeneratif Hastalıklarda Klinik ve Radyolojik Yaklaşım
- 29 April 2025
- Published by Academician Publishing
Open AccessCanpolat&Karaman&Kardaş - Temel Pediatrik Nöroradyoloji Nörometabolik ve Heredodejeneratif Hastalıklarda Klinik ve Radyolojik Yaklaşım
- Open Access
- 21 November 2023
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 15 (4) , 426-430
Neonatal Diabetes, Congenital Hypothyroidism, and Congenital Glaucoma Coexistence: A Case of GLIS3 Mutation
Neonatal diabetes and congenital hypothyroidism syndrome (NDH) is a rare condition caused by homozygous or compound heterozygous mutations in the GLIS3 gene. Small for gestational age (SGA), congenital glaucoma, polycystic kidney disease, cholestatic hepatic fibrosis, pancreatic exocrine insufficiency, developmental delay, dysmorphic facial features, sensorineural deafness, osteopenia, and skeletal anomalies are other accompanying phenotypic features in 22 cases described so far. We present a male case with neonatal diabetes, congenital hypothyroidism, congenital glaucoma, developmental delay, and facial dysmorphic features. During the patient's 17-year follow-up, no signs of exocrine pancreatic insufficiency, liver and kidney diseases, deafness, osteopenia, and bone fracture were observed. A homozygous exon 10-11 deletion was detected in the GLIS3 gene. We report one of the oldest surviving GLIS3 mutation case with main findings of neonatal diabetes and congenital hypothyroidism syndrome to contribute to the characterization of the genotypic and phenotypic spectra of the syndrome.
- 21 November 2023
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 15 (4) , 426-430
Open AccessNeonatal Diabetes, Congenital Hypothyroidism, and Congenital Glaucoma Coexistence: A Case of GLIS3 Mutation
Neonatal diabetes and congenital hypothyroidism syndrome (NDH) is a rare condition caused by homozygous or compound heterozygous mutations in the GLIS3 gene. Small for gestational age (SGA), congenital glaucoma, polycystic kidney disease, cholestatic hepatic fibrosis, pancreatic exocrine insufficiency, developmental delay, dysmorphic facial features, sensorineural deafness, osteopenia, and skeletal anomalies are other accompanying phenotypic features in 22 cases described so far. We present a male case with neonatal diabetes, congenital hypothyroidism, congenital glaucoma, developmental delay, and facial dysmorphic features. During the patient's 17-year follow-up, no signs of exocrine pancreatic insufficiency, liver and kidney diseases, deafness, osteopenia, and bone fracture were observed. A homozygous exon 10-11 deletion was detected in the GLIS3 gene. We report one of the oldest surviving GLIS3 mutation case with main findings of neonatal diabetes and congenital hypothyroidism syndrome to contribute to the characterization of the genotypic and phenotypic spectra of the syndrome.
- 15 December 2022
- Published by Aydin Pediatric Society in Trends in Pediatrics
- Vol. 3 (4) , 149-155
Serum Vitamin D and B12 Levels in School-aged Children and Adolescents with Frequent Primary Headache Attacks
Objective: Headaches are among the most frequent disorders in children and adults. Recent evidence suggests that various neurological disorders, including headaches, epilepsy, and neurodegenerative disorders, are associated with deficiencies in vitamins D and B12. In this context, this study aims to compare serum vitamin D and B12 levels in pediatric patients with migraine or tension-type headaches with those of healthy children and to explore the relationship between the frequency of headache attacks and the deficiencies in the aforementioned vitamins. Methods: The population of this retrospective study consisted of pediatric patients who presented with a headache lasting at least six months to the pediatric neurology outpatient clinics. The patients included in the study sample were categorized into two groups: Patients with migraines (n=54) and tension-type headaches (n=72). Additionally, 64 children without headaches were included in the control group. Detailed data on the features of headaches were obtained from the patients or their parents. Patients were categorized into three groups according to the frequency of the headaches as patients who had headache attacks a) once a week, b) twice or three times a week and c) ≥ four times a week. The patients were grouped into four grade levels based on their PedMIDAS scores. All participants included in the study were subjected to thyroid function tests, and vitamin D and vitamin B12 levels. Results: There was no significant difference between the groups in serum vitamin B12 levels (p>0.05). However, the median vitamin D level was significantly higher in patients with migraine-type headaches (p0.05). However, the serum vitamin D levels of patients with a PedMIDAS grade between 1 and 3 were significantly higher in patients with migraine than in those with tension-type headaches (p<0.05). The serum vitamin D levels of migraine patients with a PedMIDAS grade of 4 were significantly lower than those of migraine patients with a PedMIDAS grade of 3 (p=0.018). The migraine patients with one and 2-3 attacks per week had significantly higher vitamin D levels than those patients with tension-type headaches (p=0.031 and p<0.001, respectively). Additionally, the vitamin D levels in migraine patients with ≥4 attacks per week were significantly lower than those of migraine patients with 2-3 attacks per week (p=0.010). Conclusion: The patients with migraine and higher frequency of attacks had lower vitamin D levels.
- 15 December 2022
- Published by Aydin Pediatric Society in Trends in Pediatrics
- Vol. 3 (4) , 149-155
Serum Vitamin D and B12 Levels in School-aged Children and Adolescents with Frequent Primary Headache Attacks
Objective: Headaches are among the most frequent disorders in children and adults. Recent evidence suggests that various neurological disorders, including headaches, epilepsy, and neurodegenerative disorders, are associated with deficiencies in vitamins D and B12. In this context, this study aims to compare serum vitamin D and B12 levels in pediatric patients with migraine or tension-type headaches with those of healthy children and to explore the relationship between the frequency of headache attacks and the deficiencies in the aforementioned vitamins. Methods: The population of this retrospective study consisted of pediatric patients who presented with a headache lasting at least six months to the pediatric neurology outpatient clinics. The patients included in the study sample were categorized into two groups: Patients with migraines (n=54) and tension-type headaches (n=72). Additionally, 64 children without headaches were included in the control group. Detailed data on the features of headaches were obtained from the patients or their parents. Patients were categorized into three groups according to the frequency of the headaches as patients who had headache attacks a) once a week, b) twice or three times a week and c) ≥ four times a week. The patients were grouped into four grade levels based on their PedMIDAS scores. All participants included in the study were subjected to thyroid function tests, and vitamin D and vitamin B12 levels. Results: There was no significant difference between the groups in serum vitamin B12 levels (p>0.05). However, the median vitamin D level was significantly higher in patients with migraine-type headaches (p0.05). However, the serum vitamin D levels of patients with a PedMIDAS grade between 1 and 3 were significantly higher in patients with migraine than in those with tension-type headaches (p<0.05). The serum vitamin D levels of migraine patients with a PedMIDAS grade of 4 were significantly lower than those of migraine patients with a PedMIDAS grade of 3 (p=0.018). The migraine patients with one and 2-3 attacks per week had significantly higher vitamin D levels than those patients with tension-type headaches (p=0.031 and p<0.001, respectively). Additionally, the vitamin D levels in migraine patients with ≥4 attacks per week were significantly lower than those of migraine patients with 2-3 attacks per week (p=0.010). Conclusion: The patients with migraine and higher frequency of attacks had lower vitamin D levels.
- 30 April 2021
- Published by Galenos Yayinevi in The Journal of Pediatric Academy
- p. 39-42
Late Diagnosed Argininemia
Ammonia; It is a toxic molecule for the central nervous system resulting from the catabolism of proteins. Its excretion is provided with the urea cycle. Argininemia is a rare subtype of urea cycle disorders. Arginase enzyme catalyzes the last stage of the urea cycle, arginine; urea and ornithine are broken down. The decrease in arginase 1 (ARG1) enzyme activity is responsible for argininemia. The most common presenting symptoms of patients diagnosed with argininemia are progressive spastic diplegia, regression in developmental stages, choreoathetosis, hepatomegaly and seizures. The diagnosis of the disease can be made by detecting the elevation of arginine in body fluids together with the increase in serum ammonia. Neurological findings of these patients can be confused with cerebral palsy. In this case report, we wanted to present a patient with argininemia who was followed up with a diagnosis of cerebral palsy for a long time. Early diagnosis, restricted protein and arginine diet are life-saving in this disease. Argininemia should be kept in mind in patients with unexplained neuromotor retardation.
- 30 April 2021
- Published by Galenos Yayinevi in The Journal of Pediatric Academy
- p. 39-42
Late Diagnosed Argininemia
Ammonia; It is a toxic molecule for the central nervous system resulting from the catabolism of proteins. Its excretion is provided with the urea cycle. Argininemia is a rare subtype of urea cycle disorders. Arginase enzyme catalyzes the last stage of the urea cycle, arginine; urea and ornithine are broken down. The decrease in arginase 1 (ARG1) enzyme activity is responsible for argininemia. The most common presenting symptoms of patients diagnosed with argininemia are progressive spastic diplegia, regression in developmental stages, choreoathetosis, hepatomegaly and seizures. The diagnosis of the disease can be made by detecting the elevation of arginine in body fluids together with the increase in serum ammonia. Neurological findings of these patients can be confused with cerebral palsy. In this case report, we wanted to present a patient with argininemia who was followed up with a diagnosis of cerebral palsy for a long time. Early diagnosis, restricted protein and arginine diet are life-saving in this disease. Argininemia should be kept in mind in patients with unexplained neuromotor retardation.
- Open Access
- 25 November 2020
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 12 (4) , 393-400
Endocrine Disruptors and Polycystic Ovary Syndrome: Phthalates
We aimed to investigate a possible role of endocrine disruptors phthalates, di-2-ethylhexyl phthalate (DEHP) and mono (2-ethylhexyl) phthalate (MEHP), in polycystic ovary syndrome (PCOS) aetiopathogenesis. We also wished to evaluate the relationship between phthalates and metabolic disturbances in adolescents with PCOS. A total of 124 adolescents (63 PCOS, 61 controls, mean age: 15.2±1.5 age range: 13-19 years) were included in the study. Serum MEHP and DEHP levels were determined with HPLC method. Insulin resistance was evaluated using HOMA-IR, QUICK-I, fasting glucose /insulin ratio, Matsuda index, and total insulin levels during OGTT. Participants were further subdivided into lean and obese subgroups according to body mass index. Serum DEHP and MEHP levels were not significantly different between PCOS and control groups. The mean (95% CI) values of DEHP and MEHP were 2.62 (2.50-2.75) µg/ml vs 2.71 (2.52-2.90) µg/ml and 0.23 (0.19-0.29) µg/ml vs 0.36 (0.18-0.54) µg/ml in PCOS and the control groups respectively, p>0.05). The correlation analysis adjusted for BMI revealed that both phthalates significantly correlated with insulin resistance indices and serum triglycerides in adolescents with PCOS. Serum DEHP and MEHP concentrations were not different between adolescents with or without PCOS. However, these phthalates are associated with metabolic disturbances such as dyslipidemia and insulin resistance, independently of obesity, in girls with PCOS.
- 25 November 2020
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 12 (4) , 393-400
Open AccessEndocrine Disruptors and Polycystic Ovary Syndrome: Phthalates
We aimed to investigate a possible role of endocrine disruptors phthalates, di-2-ethylhexyl phthalate (DEHP) and mono (2-ethylhexyl) phthalate (MEHP), in polycystic ovary syndrome (PCOS) aetiopathogenesis. We also wished to evaluate the relationship between phthalates and metabolic disturbances in adolescents with PCOS. A total of 124 adolescents (63 PCOS, 61 controls, mean age: 15.2±1.5 age range: 13-19 years) were included in the study. Serum MEHP and DEHP levels were determined with HPLC method. Insulin resistance was evaluated using HOMA-IR, QUICK-I, fasting glucose /insulin ratio, Matsuda index, and total insulin levels during OGTT. Participants were further subdivided into lean and obese subgroups according to body mass index. Serum DEHP and MEHP levels were not significantly different between PCOS and control groups. The mean (95% CI) values of DEHP and MEHP were 2.62 (2.50-2.75) µg/ml vs 2.71 (2.52-2.90) µg/ml and 0.23 (0.19-0.29) µg/ml vs 0.36 (0.18-0.54) µg/ml in PCOS and the control groups respectively, p>0.05). The correlation analysis adjusted for BMI revealed that both phthalates significantly correlated with insulin resistance indices and serum triglycerides in adolescents with PCOS. Serum DEHP and MEHP concentrations were not different between adolescents with or without PCOS. However, these phthalates are associated with metabolic disturbances such as dyslipidemia and insulin resistance, independently of obesity, in girls with PCOS.
- Open Access
- 31 July 2020
- Published by The Journal of Pediatric Academy, Erciyes University
- p. 25-29
The effect of thiaminepyrophosphate levels on mortality and morbidity ın patients with stress hyperglycemia
Background: The aim of this study is to evaluate the thiamine pyrophosphate deficiency and effects on critical illness hyperglycemia in pediatric intensive care. Materials-Methods: 126 critically ill children included to the study which applied to Erciyes University Faculty of Medicine, Department of Pediatric Intensive Care Unit (ICU). Age, sex, diagnosis and presence of malnutrition in admission to ICU; Pediatric risk of Mortality III (PRISM III) and Pediatric Logistic Organ Dysfunction (PELOD) scores; mechanical ventilation and length of stay in ICU was evaluated. Blood glucose, thiamine pyrophosphate, cortisol, insulin, C-peptide, HbA1c level, serum lactate in blood gas were analyzed at the time of application. Results: The patients grouped based on blood glucose levels, the group whose glucose level in blood is more than 150 mg/dl (n:75); PRISM and PELOD scores were high, mechanical ventilation and length of stay in intensive care were longer, thiamine pyrophosphate levels were lower (p<0.001, p=0.005, p=0.008, p<0.001, p150 mg/dl (n:51) and thiamine pyrophosphate <180 nmol/l is together; mortality increases 3.342-fold and the case was statistically significant (p=0.014). The group whose glucose level in blood is more than 150 mg/dl respectively, insulin, c-peptide and cortisol levels found high and the findings were statistically significant (p<0.001, p=0.005, p=0.040). Conclusion: Stress hyperglycemia is a common situation seen in critically ill patients as a cause of worse clinical outcomes. Identification of stress hyperglycemia due to thiamine deficiency is difficult but it will shed light on the treatment of critically ill children.
- 31 July 2020
- Published by The Journal of Pediatric Academy, Erciyes University
- p. 25-29
Open AccessThe effect of thiaminepyrophosphate levels on mortality and morbidity ın patients with stress hyperglycemia
Background: The aim of this study is to evaluate the thiamine pyrophosphate deficiency and effects on critical illness hyperglycemia in pediatric intensive care. Materials-Methods: 126 critically ill children included to the study which applied to Erciyes University Faculty of Medicine, Department of Pediatric Intensive Care Unit (ICU). Age, sex, diagnosis and presence of malnutrition in admission to ICU; Pediatric risk of Mortality III (PRISM III) and Pediatric Logistic Organ Dysfunction (PELOD) scores; mechanical ventilation and length of stay in ICU was evaluated. Blood glucose, thiamine pyrophosphate, cortisol, insulin, C-peptide, HbA1c level, serum lactate in blood gas were analyzed at the time of application. Results: The patients grouped based on blood glucose levels, the group whose glucose level in blood is more than 150 mg/dl (n:75); PRISM and PELOD scores were high, mechanical ventilation and length of stay in intensive care were longer, thiamine pyrophosphate levels were lower (p<0.001, p=0.005, p=0.008, p<0.001, p150 mg/dl (n:51) and thiamine pyrophosphate <180 nmol/l is together; mortality increases 3.342-fold and the case was statistically significant (p=0.014). The group whose glucose level in blood is more than 150 mg/dl respectively, insulin, c-peptide and cortisol levels found high and the findings were statistically significant (p<0.001, p=0.005, p=0.040). Conclusion: Stress hyperglycemia is a common situation seen in critically ill patients as a cause of worse clinical outcomes. Identification of stress hyperglycemia due to thiamine deficiency is difficult but it will shed light on the treatment of critically ill children.
- Open Access
- 1 June 2019
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 11 (2) , 140-148
Comparison of Treatment Regimens in Management of Severe Hypercalcemia Due to Vitamin D Intoxication in Children
Objective: No large study has been conducted to date to compare the effectiveness of prednisolone, alendronate and pamidronate as first-line treatment in children with hypercalcemia due to vitamin D intoxication. The aim was to perform a multicenter, retrospective study assessing clinical characteristics and treatment results. Methods: A standard questionnaire was uploaded to an online national database system to collect data on children with hypercalcemia (serum calcium level > 10.5 mg/dL) due to vitamin D intoxication [serum 25-hydroxyvitamin D (25(OH)D) level > 150 ng/mL] who were treated in pediatric endocrinology clinics. Results: Seventy-four children [median (range) age 1.06 (0.65-1.60) years, 45 males (61 %) from II centers] were included. High-dose vitamin D intake was evident in 77% of the cases. At diagnosis, serum calcium, phosphorus, alkaline phosphatase, 25(OH)D and parathyroid hormone concentrations were 15 +/- 3.2 mg/dl., 5.2 +/- 1.2 mg/dL, 268 +/- 132 IU/L, 322 (236-454) ng/ml, and 5.5 (3-10.5) pg/mL, respectively. Calcium levels showed moderate correlation with 25(OH)D levels (r(s) = 0.402, p <0.001). Patients were designated into five groups according to the initial specific treatment regimens (hydration-only, prednisolone, alendronate, pamidronate, and combination). Need for another type of specific drug treatment was higher in children who initially received prednisolone (p <0.000). Recurrence rate of hypercalcemia was significantly lower in children who were treated with pamidronate (p=0.02). Conclusion: Prednisolone is less effective in the treatment of children with severe hypercalcaemia secondary to vitamin D intoxication and timely implementation of other treatment regimens should be considered.
- 1 June 2019
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 11 (2) , 140-148
Open AccessComparison of Treatment Regimens in Management of Severe Hypercalcemia Due to Vitamin D Intoxication in Children
Objective: No large study has been conducted to date to compare the effectiveness of prednisolone, alendronate and pamidronate as first-line treatment in children with hypercalcemia due to vitamin D intoxication. The aim was to perform a multicenter, retrospective study assessing clinical characteristics and treatment results. Methods: A standard questionnaire was uploaded to an online national database system to collect data on children with hypercalcemia (serum calcium level > 10.5 mg/dL) due to vitamin D intoxication [serum 25-hydroxyvitamin D (25(OH)D) level > 150 ng/mL] who were treated in pediatric endocrinology clinics. Results: Seventy-four children [median (range) age 1.06 (0.65-1.60) years, 45 males (61 %) from II centers] were included. High-dose vitamin D intake was evident in 77% of the cases. At diagnosis, serum calcium, phosphorus, alkaline phosphatase, 25(OH)D and parathyroid hormone concentrations were 15 +/- 3.2 mg/dl., 5.2 +/- 1.2 mg/dL, 268 +/- 132 IU/L, 322 (236-454) ng/ml, and 5.5 (3-10.5) pg/mL, respectively. Calcium levels showed moderate correlation with 25(OH)D levels (r(s) = 0.402, p <0.001). Patients were designated into five groups according to the initial specific treatment regimens (hydration-only, prednisolone, alendronate, pamidronate, and combination). Need for another type of specific drug treatment was higher in children who initially received prednisolone (p <0.000). Recurrence rate of hypercalcemia was significantly lower in children who were treated with pamidronate (p=0.02). Conclusion: Prednisolone is less effective in the treatment of children with severe hypercalcaemia secondary to vitamin D intoxication and timely implementation of other treatment regimens should be considered.
- Open Access
- 19 March 2018
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 10 (4) , 382-386
A Rare Cause of Hypothalamic Obesity, Rohhad Syndrome: 2 Cases
Rapid-onset obesity with hypoventilation, hypothalamic dysfunction and autonomic dysregulation (ROHHAD) syndrome is a rare disease that is difficult to diagnosis and distinguish from genetic obesity syndromes. The underlying causes of the disease have not been fully explained. Hypothalamic dysfunction causes endocrine problems, respiratory dysfunction and autonomic alterations. Currently there are around 80 reported patients although this is likely due to underdiagnosis due to lack of recognition. We present two female patients suspected of ROHHAD due to weight gain starting in early childhood. Clinical and biochemical findings such as respiratory and circulatory dysfunction, hypothalamic hypernatremia, central hypothyrodism, hyperprolactinemia and central early puberty in these patients matched the criteria for ROHHAD syndrome. ROHHAD syndrome should be considered in the differential diagnosis of monogenic obesity.
- 19 March 2018
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 10 (4) , 382-386
Open AccessA Rare Cause of Hypothalamic Obesity, Rohhad Syndrome: 2 Cases
Rapid-onset obesity with hypoventilation, hypothalamic dysfunction and autonomic dysregulation (ROHHAD) syndrome is a rare disease that is difficult to diagnosis and distinguish from genetic obesity syndromes. The underlying causes of the disease have not been fully explained. Hypothalamic dysfunction causes endocrine problems, respiratory dysfunction and autonomic alterations. Currently there are around 80 reported patients although this is likely due to underdiagnosis due to lack of recognition. We present two female patients suspected of ROHHAD due to weight gain starting in early childhood. Clinical and biochemical findings such as respiratory and circulatory dysfunction, hypothalamic hypernatremia, central hypothyrodism, hyperprolactinemia and central early puberty in these patients matched the criteria for ROHHAD syndrome. ROHHAD syndrome should be considered in the differential diagnosis of monogenic obesity.